News

Stories

See all

Lilly Manufacturing Facility

COVID-19 Update on Insulin Affordability and Supply

View Story

Updates: Lilly's Global COVID-19 Response

View Story

Dave Ricks media downloads portrait

Dave Ricks Shares Thoughts on 2019

View Story

In Bolivia, Life for a Child Helps a Youth Achieve His Dream

View Story

Gemologist Benefits from Insulin Affordability Program

View Story

Lilly Scientist Meets Patient Helped by Cancer Discovery

View Story


  1. 1

Press Releases

See all

Updates from Lilly about insulin supply and affordability

March 24, 2020

Tags |  Product

INDIANAPOLIS , March 24, 2020 /PRNewswire/ -- To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability: As we announced on March 3 , Lilly does not




Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic

March 23, 2020

Tags |  Corporate

INDIANAPOLIS , March 23, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company will delay most new study starts and pause enrollment in most ongoing studies.




Lilly to Provide Drive-Through COVID-19 Testing for Indianapolis Health Care Workers

March 22, 2020

Tags |  Corporate

INDIANAPOLIS , March 22, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will offer drive-through testing for SARS-CoV-2, the virus that causes COVID-19, to Indianapolis area health care workers beginning Monday, March 23 , as a service to the community and in an effort to protect health care




US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes

March 20, 2020

Tags |  Product

RIDGEFIELD, Conn. and INDIANAPOLIS, March 20, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1